Venus Concept 2025 Q3 Earnings Narrowed Loss Per Share Amid Widened Net Loss

Venus Concept (VERO) reported Q3 2025 earnings marked by a narrowed loss per share but a significantly wider net loss. The company’s results fell short of expectations, with no guidance provided for the full year. Strategic shifts and operational challenges weighed on performance, despite a 510(k) clearance for its Venus NOVA platform.

Revenue

Venus Concept’s total revenue declined by 8.2% to $13.78 million in Q3 2025, reflecting weaker demand in the Venus Hair segment and broader market headwinds. Venus Prime / Subscription-Systems led with $2.94 million in revenue, while Products-Systems contributed $7.86 million. Additional revenue streams included $2.33 million from Products-Other and $647,000 from Services. The decline was driven by reduced sales in the hair restoration business, customer financing pressures, and economic uncertainty.

Earnings/Net Income

The company narrowed its loss per share to $12.14 in Q3 2025, a 7.3% improvement from $13.10 in the prior-year period. However, the net loss widened to $22.55 million, a 142.4% increase from $9.30 million in Q3 2024. This divergence was attributed to higher operating expenses, including legal fees related to the pending Venus Hair business sale, and a noncash loss on debt extinguishment. The sustained losses over nine consecutive years underscore ongoing financial challenges.

Post-Earnings Price Action Review

The strategy of buying Venus Concept shares on earnings dates and holding for 30 days has historically underperformed, with a 3-year cumulative return of -68.77% and an average quarterly return of -22.61%. Despite the company’s reported revenue growth, the stock has struggled, tumbling 9.84% over the latest week and 26.89% month-to-date. This weak price action reflects investor skepticism toward the company’s ability to reverse its financial trajectory.

CEO Commentary

CEO Rajiv De Silva highlighted a 2% year-over-year growth in energy-based device (EBD) sales, attributing it to improved sales efficiency and a focus on core products like Bliss MAX and Versa PRO. However, he acknowledged softness in the Venus Hair segment and broader economic pressures. De Silva emphasized the launch of Venus NOVA, a next-generation platform cleared for commercial use in December, as a catalyst for sequential growth. He also noted delays in the Venus Hair business sale and ongoing legal challenges, which have strained operating expenses.

Guidance

Venus Concept did not provide full-year 2025 financial guidance, citing active dialogue with lenders, strategic evaluations, and market uncertainties. However, management expressed optimism for sequential growth in Q4, driven by the limited commercial launch of Venus NOVA.

Additional News

The pending sale of the Venus Hair business to MHG Co. Ltd. remains a focal point, with the company seeking court assistance to resolve transaction delays. Separately, Venus Concept secured $11.5 million in debt-to-equity exchanges in Q3 2025, reducing total debt obligations to $30.1 million—a 24% decline from $39.7 million as of December 31, 2024. The company also received FDA 510(k) clearance for Venus NOVA, its first product under a new R&D strategy, positioning it to target the GLP-1 medication-driven body and skin market.

Article Polishing

The earnings report underscores Venus Concept’s struggle to balance innovation with financial stability. While the Venus NOVA launch and debt reduction efforts offer hope, persistent losses and market uncertainties remain significant hurdles. Investors are advised to monitor the Venus Hair business sale and the commercial performance of Venus NOVA as key indicators of the company’s turnaround potential.